An algorithm for the treatment of schizophrenia in the correctional setting: The forensic algorithm project

Journal of Clinical Psychiatry

Volumn 61, Issue 10, 2000, Pages 767-783

  Buscema, C A ^a   Abbasi, Q A ^a   Barry, D J ^a   Lauve, T H ^a  

^a Box 300 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZATROPINE; BENZATROPINE MESILATE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLONAZEPAM; CLONIDINE; CLOZAPINE; DESIPRAMINE; DIPHENHYDRAMINE; DONEPEZIL; FLUOXETINE; FLUVOXAMINE MALEATE; GABAPENTIN; HALOPERIDOL; HYDROXYZINE; LAMOTRIGINE; LITHIUM; LORAZEPAM; LOXAPINE SUCCINATE; METHYLPHENIDATE; MIRTAZAPINE; NALTREXONE; NEFAZODONE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PEMOLINE MAGNESIUM; PERPHENAZINE; PHENELZINE; PHENYTOIN; PIMOZIDE; PROPRANOLOL; QUETIAPINE; RISPERIDONE; SERTRALINE; THIORIDAZINE; TOPIRAMATE; TRAZODONE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VENLAFAXINE; ZOLPIDEM TARTRATE;

AGGRESSION; ALGORITHM; ARTICLE; AUTOMUTILATION; CLINICAL FEATURE; DEPRESSION; DISEASE SEVERITY; ELECTROCONVULSIVE THERAPY; EXTRAPYRAMIDAL SYMPTOM; FORENSIC PSYCHIATRY; HUMAN; HYPOMANIA; NEUROLEPTIC MALIGNANT SYNDROME; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PATIENT EDUCATION; PERSONALITY DISORDER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRISONER; PSYCHOTHERAPY; SCHIZOPHRENIA; SUPPORT GROUP; SYMPTOM; TARDIVE DYSKINESIA;

EID: 0033759313     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v61n1009     Document Type: Article

References (123)

1. Kendra's LawP: The process for obtaining assisted outpatient treatment
2. Psychopathological effects of solitary confinement
3. Effects of sensory deprivation in psychiatric seclusion and solitary confinement
4. Practice guidelines in forensic psychiatry
5. The forensic psychiatric aspects of schizophrenia
6. Practice Guideline for the Treatment of Patients With Schizophrenia
7. Translating research into practice: The schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations
8. Expert Consensus Guideline Series: Treatment of Schizophrenia
9. The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms
10. The Brief Psychiatric Rating Scale
11. Global Assessment of Functioning (GAF) Scale
12. Olanzapine and haloperidol in first-episode psychosis
13. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia
14. The positive-negative dimension in schizophrenia: Its validity and significance
15. Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenics
16. Relations among clinical scales in schizophrenia
17. Optimizing treatment with clozapine
18. Schizoaffective disorder: Mixing moods and madness
19. Recent advances in the pharmacotherapy of schizophrenia
20. Negative symptoms in schizophrenia
21. Modified scale for the assessment of negative symptoms
22. The Scale for the Assessment of Negative Symptoms (SANS)
23. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia
24. Maximizing clozapine therapy: Managing side effects
25. Revisiting neuroleptic malignant syndrome
26. Mortality in current and former users of clozapine
27. The Overt Aggression Scale for the objective rating of verbal and physical aggression
28. Critical review of GABA-ergic drugs in the treatment of schizophrenia
29. The effect of propranolol on uncontrolled rage outbursts in children and adolescents with organic brain dysfunction
30. Management of violence in schizophrenia
31. The role of typical and atypical antipsychotic medications in the management of agitation and aggression
32. 2 receptors: Implications for the therapeutics of schizophrenia
33. An orally administrated opiate blocker, naltrexone, attenuates self injurious behavior
34. Can aggressive behavior in humans be modified by beta blockers?
35. Beta-adrenergic blockers for the control of aggressive behaviors in patients with chronic schizophrenia
36. Antiaggressive effect of adjunctive clonazepam in schizophrenia associated with seizure disorder
37. Preventive aggression devices (PADS): Ambulatory restraints as an alternative to seclusion
38. Reliability and validity of a brief instrument for assessing post-tranmatic stress disorder
39. Eye movement desensitization and reprocessing treatment of rape trauma: A case report
40. The neuropsychiatric evaluation of the closed head injury of transient type (CHIT)
41. The role of negative symptoms and cognitive dysfunction in schizophrenia outcome
42. Neurocognitive deficits and neurological signs in schizophrenia
43. Cognitive function in schizophrenia: Association with negative and positive symptoms
44. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
45. Cholinesterase inhibitors: A new class of psychotropic compounds
46. Illness severity and treatment services for dually diagnosed severely mentally ill outpatients
47. Substance abuse in schizophrenia: A review
48. Eye movement desensitization and reprocessing (EMDR): Evaluation of controlled PTSD research
49. Schizoaffective disorder: A form of schizophrenia or affective disorder?
50. Valproate in psychiatric disorders: Literature review and clinical guidelines
51. Treatment of resistant schizophrenia with valproate and neuroleptic drugs
52. Paroxetine treatment of generalized social phobia (social anxiety disorder): A randomized controlled trial
53. Electroconvulsive therapy
54. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: A rationale and hypothesis
55. Olanzapine and negative symptoms
56. Quetiapine (Seroquel): An effective and well-tolerated atypical antipsychotic
57. New atypical antipsychotic medications
58. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: Impact on risk-benefit assessment
59. Gabapentin treatment of mood disorders: A preliminary study
60. Neuroleptic-valproic acid combination in treatment of psychotic symptoms: A three-case report
61. Neuropsychiatry
62. Sertraline treatment of comorbid post-traumatic stress disorder and alcohol dependence
63. Sertraline efficacy in depressed combat veterans with posttraumatic stress disorder
64. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine
65. Risperidone, negative symptoms and cognitive deficit in schizophrenia: An open study
66. Fluoxetine treatment in children and adults with autistic disorder and mental retardation
67. Sertraline in adults with pervasive developmental disorders: A prospective open-label investigation
68. Integration of the evaluation and management of the transient closed head injury patient: Some directions
69. Dialectical behavior therapy: An integrative approach to the treatment of borderline personality disorder
70. The dialectics of effective treatment of borderline personality disorder
71. The expanding indications for clozapine
72. Combining risperidone with standard neuroleptics for refractory schizophrenic patients
73. Clozapine reduces violence and persistent aggression in schizophrenia
74. The use of clozapine in the treatment of aggressive schizophrenia
75. Clozapine reduces severe selfmutilation and aggression in psychotic patients with borderline personality disorder
76. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine
77. Clinical efficacy of clozapine in treatment-refractory schizophrenia: An overview
78. Blood clozapine levels elevated by fluvoxamine: Potential for side effects and lower clozapine dosage
79. Reducing clozapine-related morbidity and mortality: 5 Years of experience with the Clozaril National Registry
80. Weight gain with clozapine treatment
81. Hyperglycemia associated with olanzapine
82. Olanzapine-induced ketoacidosis with diabetes mellitus
83. Effect of clozapinequetiapine combination therapy on weight and glycaemic control
84. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges
85. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients
86. Risperidone in the treatment of schizophrenia
87. Treatment of schizoaffective disorder and schizophrenia and mood symptoms
88. Clinical experience with gabapentin in patients with bipolar or schizoaffective disorder: Results of an open-label study
89. Lamotrigine in the treatment of schizoaffective disorder
90. New developments in the pharmacologic treatment of schizoaffective disorder
91. Management of depression in schizophrenia
92. Hematologic side effects of psychotropics
93. Drug interactions: Phenytoin
94. The Hare PCL-R: Some issues concerning its use and misuse
95. Naltrexone maintenance treatment for opioid dependence (Cochrane Review)
96. Pimozide augmentation for the treatment of schizophrenic patients who are responders to clozapine
97. Pimozide augmentation in a patient with drug-resistant psychosis previously treated with olanzapine
98. Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients
99. 2 occupancy decides antipsychotic dosage
100. Strategies for implementing psychiatric medication algorithms in the public sector
101. Texas Medication Algorithm Project: Definitions, rationale, and methods to develop medication algorithms
102. Consensus guidelines in the treatment of major depressive disorder
103. Medication treatment for the severely and persistently mentally ill: The Texas Medication Algorithm Project
104. Reduced frequency of aggressive behavior in forensic patients in a social learning program
105. Effectiveness of inpatient treatment programs for mentally ill adults in public psychiatric facilities
106. Implementing outcomes management systems in mental health settings
107. Principles for assessment of patient outcomes in mental health care
108. Facilitating compliance with antipsychotic medication